Ratnadeep Basu1, Marko Poglitsch2, Haran Yogasundaram1, Jissy Thomas3, Brian H Rowe4, Gavin Y Oudit5. 1. Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Canada; Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada. 2. Attoquant Diagnostics, Vienna, Austria. 3. Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada. 4. Department of Emergency Medicine and School of Public Health, University of Alberta, Edmonton, Canada. 5. Division of Cardiology, Department of Medicine, University of Alberta, Edmonton, Canada; Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Canada. Electronic address: gavin.oudit@ualberta.ca.
Abstract
BACKGROUND: The renin-angiotensin system (RAS) is activated in heart failure (HF) and inhibition of RAS is a mainstay therapy for HF. Angiotensin-converting enzyme 2 (ACE2) and its product, angiotensin 1-7 (Ang-[1-7]), are important negative regulators of the RAS. OBJECTIVES: A comprehensive examination of angiotensin peptide levels and therapeutic effects of recombinant human ACE2 (rhACE2) on peptide metabolism was evaluated in human plasma and explanted heart tissue from patients with HF. METHODS: Using prospective cohorts with chronic (n = 59) and acute (n = 42) HF, plasma angiotensin analysis was performed using a unique liquid chromatography-mass spectrometry/mass spectroscopy method quantifying circulating and equilibrium levels. Angiotensin II (Ang II) metabolism was examined in human explanted hearts with dilated cardiomyopathy (n = 25). RESULTS: The dynamic range of the RAS was large, with equilibrium angiotensin levels being 8- to 10-fold higher compared with circulating angiotensin levels. In chronic HF patients receiving ACE inhibition, plasma Ang II was suppressed and plasma Ang-(1-7) was elevated, whereas acute HF and patients receiving angiotensin receptor blocker had higher plasma Ang II with lower Ang-(1-7) levels. Suppressed Ang-(1-7)/Ang II ratio was associated with worsening HF symptoms and longer hospitalization. Recombinant human ACE2 effectively metabolized Ang-(1-10) and Ang II into Ang-(1-9) and Ang-(1-7), respectively. Myocardial Ang II levels in explanted human hearts with dilated cardiomyopathy were elevated despite ACE inhibition with elevated chymase activity, and Ang II was effectively converted to Ang-(1-7) by rhACE2. CONCLUSIONS: Plasma angiotensin peptides represent a dynamic network that is altered in HF and in response to rhACE2. An increased plasma Ang-(1-7) level is linked to ACE inhibitor use, whereas acute HF reduced Ang-(1-7) levels and suppressed the Ang-(1-7)/Ang II ratio. Increased chymase activity elevated Ang II levels in failing human hearts. Use of rhACE2 effectively normalized elevated Ang II while increasing Ang-(1-7) and Ang-(1-9) levels.
BACKGROUND: The renin-angiotensin system (RAS) is activated in heart failure (HF) and inhibition of RAS is a mainstay therapy for HF. Angiotensin-converting enzyme 2 (ACE2) and its product, angiotensin 1-7 (Ang-[1-7]), are important negative regulators of the RAS. OBJECTIVES: A comprehensive examination of angiotensin peptide levels and therapeutic effects of recombinant humanACE2 (rhACE2) on peptide metabolism was evaluated in human plasma and explanted heart tissue from patients with HF. METHODS: Using prospective cohorts with chronic (n = 59) and acute (n = 42) HF, plasma angiotensin analysis was performed using a unique liquid chromatography-mass spectrometry/mass spectroscopy method quantifying circulating and equilibrium levels. Angiotensin II (Ang II) metabolism was examined in human explanted hearts with dilated cardiomyopathy (n = 25). RESULTS: The dynamic range of the RAS was large, with equilibrium angiotensin levels being 8- to 10-fold higher compared with circulating angiotensin levels. In chronic HFpatients receiving ACE inhibition, plasma Ang II was suppressed and plasma Ang-(1-7) was elevated, whereas acute HF and patients receiving angiotensin receptor blocker had higher plasma Ang II with lower Ang-(1-7) levels. Suppressed Ang-(1-7)/Ang II ratio was associated with worsening HF symptoms and longer hospitalization. Recombinant humanACE2 effectively metabolized Ang-(1-10) and Ang II into Ang-(1-9) and Ang-(1-7), respectively. Myocardial Ang II levels in explanted human hearts with dilated cardiomyopathy were elevated despite ACE inhibition with elevated chymase activity, and Ang II was effectively converted to Ang-(1-7) by rhACE2. CONCLUSIONS: Plasma angiotensin peptides represent a dynamic network that is altered in HF and in response to rhACE2. An increased plasma Ang-(1-7) level is linked to ACE inhibitor use, whereas acute HF reduced Ang-(1-7) levels and suppressed the Ang-(1-7)/Ang II ratio. Increased chymase activity elevated Ang II levels in failing human hearts. Use of rhACE2 effectively normalized elevated Ang II while increasing Ang-(1-7) and Ang-(1-9) levels.
Authors: Jessica L Faulkner; Daisy Harwood; Lily Bender; Lenee Shrestha; Michael W Brands; M Jane Morwitzer; Simone Kennard; Galina Antonova; Eric J Belin de Chantemèle Journal: Hypertension Date: 2018-12 Impact factor: 10.190
Authors: Ravindra K Sharma; Bruce R Stevens; Alexander G Obukhov; Maria B Grant; Gavin Y Oudit; Qiuhong Li; Elaine M Richards; Carl J Pepine; Mohan K Raizada Journal: Hypertension Date: 2020-08-12 Impact factor: 10.190
Authors: Yaqian Duan; Eleni Beli; Sergio Li Calzi; Judith L Quigley; Rehae C Miller; Leni Moldovan; Dongni Feng; Tatiana E Salazar; Sugata Hazra; Jude Al-Sabah; Kakarla V Chalam; Thao Le Phuong Trinh; Marya Meroueh; Troy A Markel; Matthew C Murray; Ruchi J Vyas; Michael E Boulton; Patricia Parsons-Wingerter; Gavin Y Oudit; Alexander G Obukhov; Maria B Grant Journal: Stem Cells Date: 2018-07-15 Impact factor: 6.277
Authors: Christina Binder; Marko Poglitsch; Franz Duca; René Rettl; Theresa Marie Dachs; Daniel Dalos; Lore Schrutka; Benjamin Seirer; Luciana Camuz Ligios; Christophe Capelle; Roza Badr Eslam; Hong Qin; Christian Hengstenberg; Diana Bonderman Journal: J Pers Med Date: 2021-05-03
Authors: Sarfaraz Ahmad; Henry A Punzi; Kendra N Wright; Leanne Groban; Carlos M Ferrario Journal: Mol Cell Endocrinol Date: 2021-03-30 Impact factor: 4.369